PRESS RELEASE published on 11/12/2025 at 07:30, 4 months 10 days ago Evotec receives milestone payment from Bristol Myers Squibb following IND acceptance in strategic protein degradation partnership Evotec receives US$ 5m milestone payment from Bristol Myers Squibb for IND acceptance in protein degradation partnership, advancing drug candidate towards Phase 1 clinical trial Evotec Milestone Payment Bristol Myers Squibb Protein Degradation IND Acceptance
BRIEF published on 11/05/2025 at 07:35, 4 months 17 days ago Evotec SE annonce des résultats solides pour les 9 premiers mois de l'année 2025, avec une orientation stratégique. Evotec SE Croissance Des Produits Biologiques Alliances Stratégiques Résultats 9M 2025 Transaction Sandoz
BRIEF published on 11/05/2025 at 07:35, 4 months 17 days ago Evotec SE Reports Resilient 9M 2025 Results with Strategic Focus Strategic Alliances Evotec SE Biologics Growth 9M 2025 Results Sandoz Transaction
PRESS RELEASE published on 11/05/2025 at 07:30, 4 months 17 days ago Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities Evotec SE reports 9M 2025 results with €535.1m group revenues, strong scientific advancements, landmark industry transaction, and confirmed 2025 guidance and 2028 outlook Strategic Priorities Evotec SE 9M Results 2028 Outlook Landmark Industry Transaction
BRIEF published on 11/04/2025 at 22:10, 4 months 17 days ago Evotec signe un accord historique avec Sandoz et vise des revenus substantiels. Evotec Biosimilaires Industrie Pharmaceutique Technologie De Fabrication Sandoz
BRIEF published on 11/04/2025 at 22:10, 4 months 17 days ago Evotec Signs Milestone Agreement with Sandoz, Eyes Substantial Revenue Pharmaceutical Industry Biosimilars Evotec Manufacturing Technology Sandoz
PRESS RELEASE published on 11/04/2025 at 22:05, 4 months 17 days ago In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties Evotec SE signs landmark agreement with Sandoz, leading to over US$650m in payments plus royalties. Deal includes acquisition of manufacturing site and technology license fees Evotec SE Payments Biosimilars Agreement Sandoz
BRIEF published on 10/29/2025 at 09:50, 4 months 24 days ago Evotec SE publiera ses résultats financiers du troisième trimestre 2025 le 5 novembre. Résultats Financiers Evotec SE Conférence Téléphonique Sciences De La Vie Performances 2025
BRIEF published on 10/29/2025 at 09:50, 4 months 24 days ago Evotec SE to Release Q3 2025 Financial Results on November 5th Financial Results Conference Call Life Sciences Evotec SE 2025 Performance
PRESS RELEASE published on 10/29/2025 at 09:45, 4 months 24 days ago Evotec SE to announce results for the first nine months 2025 on 05 November 2025 Evotec SE to announce results for the first nine months 2025 on 05 November 2025. The Company will hold a conference call in English to discuss the interim statement Conference Call Financial Report Evotec SE Results Interim Statement
Published on 03/20/2026 at 13:30, 2 days 7 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 8 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 8 hours 32 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 22 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA